OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…

On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…

As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…

As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…

By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…

The start of a new year is a time for reflection and looking to the future. This is an ideal…

Introduction Data from a new study presented at the European Society for Medical Oncology (ESMO) meeting and published in Nature…

Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…